Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose decitabine plus valproic acid in allogeneic hematopoietic stem cell transplantation for hematologic malignancies
ChiCTR1800014888Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of decitabine and valproic acid in hematopoietic malignancies (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: myelogram and occurrence of graft-versus-host disease. Started Jan 2018; status: recruiting.
02
Drugs
decitabinevalproic acid
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on ChiCTR1800014888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014888.